T-cell engagers (TCEs) are transforming cancer immunotherapy, but their unique mechanisms—such as dual-targeting specificity and complex immune modulation—demand innovative preclinical evaluation approaches to ensure successful clinical translation. Traditional preclinical models often struggle to mimic the complexity of human immune responses, leading to gaps in predicting efficacy and safety. This webinar will explore advanced strategies to bridge these gaps, equipping you with tools to accelerate TCE development while proactively addressing translational risks.

Webinar Outline:

• Navigating progress and challenges in TCE development

• Introducing next-generation models such as PBMC-NCG, PBMC-NCG-MHC-DKO and huHSC-NCG-hIL15

• Discussing innovative safety assessment strategies using CD3EDG humanized systems and HSC-reconstituted models

• Presenting integrated preclinical evaluation platform for TCEs